Abstract
When present at diagnosis or when developing in the course of disease, the presence of bone metastases from prostate cancer is generally considered an indication to begin endocrine therapy, as this is clearly the most effective form of treatment for this problem. Endocrine therapy can stop progression of prostate cancer in 80–85% of cases. Endocrine therapy can relieve pain, prevent pathologic fractures, and prevent neurologic complications from bone metastases from prostate cancer. Rarely, bone scans may become normal after the start of endocrine therapy, but partial improvement or stabilization of bone scans are more commonly seen. While endocrine therapy has been the first line of treatment of metastatic prostate cancer for the past 50 years, the recent development of newer forms of endocrine therapy have increased the options in the past few years. In addition to orchiectomy and estrogens, newer alternatives include inhibitors of androgen synthesis, the class of agents termed “antiandrogens”, and leutinizing hormone releasing-hormone (LHRH) analogues either alone or in combination. Orchiectomy causes a prompt fall in serum testosterone and is regarded by many as the “standard” form of endocrine therapy, but there is concern about the psychologic impact of surgery. Estrogens are being used less frequently today because of their real or potential side-effects, including cardiovascular and thromboembolic’complications. The development of analogues of LHRH has resulted in another major choice for endocrine therapy, and one which is therapeutically equivalent to orchiectomy or estrogens. Since LHRH analogues may cause an early rise or “flare” in serum testosterone before it drops to castrate level, these agents should not be given alone to patients with severe pain or neurologic problems. The newly available antiandrogen flutamide can block the “flare”, and may also improve survival when used with LHRH analogues or orchiectomy, especially when disease is less advanced. Not all studies of “combination therapy” support this conclusion. However, the use of flutamide is increasing significantly in the United States. Both the LHRH analogues and flutamide are fairly safe, but they are very expensive. Their use, in combination, is likely to become a progressively more common form of initial endocrine therapy in the future. The growing application of prostate specific antigen (PSA) as a tumor marker for prostate cancer has made the difficulty in interpreting changes in bone scans a much less critical problem in determining response to endocrine or other forms of therapy for advanced prostate cancer.
Keywords
- Prostatic Cancer
- Serum Testosterone
- Advanced Prostatic Cancer
- Metastatic Prostate Cancer
- Cyproterone Acetate
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Huggins C. and Hodges C.V., Studies on prostatic cancer. 1. The effect of castration, estrogen and of androgen injections on serum phosphatases in metastatic carcinoma of the prostate, Recent Results Cancer Res. 1:293 (1941).
Murphy G.P. and Slack N.H., The questionable use of hormone therapy in advanced carcinoma of the prostate, Urol. Clin. N. Amer. 7:631–638 (1980).
Scott W.W., Menon M. and Walsh P.C., Hormonal therapy for prostatic cancer, Cancer 45:1929–1936 (1980).
Menon M. and Walsh P.C., Hormonal therapy for prostatic cancer, in: “Prostate Cancer,” pp. 175–200, Murphy G.P. ed., PSG Pub. Co., MA. (1979).
Maatman T.J., Gupta M.K. and Montie J.E., Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate, J. Urol. 133:620–621 (1985).
Hsueh A.J.W., Dufau M.L. and Catt K.J., Direct inhibitory effect of estrogen on Leydig cell function of hypohysectomized rats, Endocrin. 103:1096–1102 (1978).
Prout G.R., Kliman B., Daly J.J., et al., Endocrine changes after diethylstilbestrol therapy. Effects on prostatic neoplasm and pituitary gonadal axis, Urol. 7:148–155 (1976).
Shearer R.J., Hendry W.F., Sommerville I.F., et al., Plasma testosterone: An accurate monitor of hormone treatment in prostatic cancer, Brit. J. Urol. 45:668–677 (1973).
Veterans Administration Cooperative Urological Research Group, Treatment and survival of patients with cancer of the prostate, Surg. Gyn. Obs. 124:1011–1017 (1967).
De Voogt H., Smith P.H., Pavonel-Macaluso M., et al., Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: Results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762, J. Urol. 135:303–307 (1986).
Pont A., William P.L., Loose D.S., Feldman D., Reitz R.E., Bochra C. and Stevens D.A., Ketoconazole blocks adrenal steroid synthesis, Ann. Intern. Med. 97:370 (1982).
Trachtenberg J. Ketoconazole therapy in advanced prostatic cancer, J. Urol. 132:61 (1984).
Pont A., Long-term experience with high-dose ketoconazole therapy in patients with Stage D2 prostatic carcinoma, J. Urol. 137:902–904 (1987).
Sanford E.J., Drago J.R., Rohner T.J., Jr., Santen R. and Lipton A., Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma, J. Urol. 115–170 (1976).
Worgul T.J., Santen R.J., Samojlik E., Veldhuis J.D., Lipton A., Harvey H.A., Dago J.R. and Rohner T.J., Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma, J. Urol. 129:51 (1983).
Walsh P.C. and Siiteri P.K., Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate, J. Urol. 114:254–256 (1975).
Wein A.J. and Murphy J.J., Experience in the treatment of prostatic carcinoma with cyproterone acetate, J. Urol. 109:68 (1973).
Jacobi G.H., Altwein J.E., Kurth K.H., Basting R. and Hohenfellner R., Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a Phase III randomized trial, Brit. J. Urol. 52:208 (1980).
Geller J., Albert J. and Yen S.S.C., Treatment of advanced cancer of the prostate with megestrol acetate, Urology 12:537–541 (1978).
Geller J., Albert J., Yen S.S.C., et al., Medical castration of males with megestrol acetate and small doses of diethylstilbestrol, J. Clin. Endocrin. Metab. 52:576–580 (1981).
Sogani P.C., Vagaiwala M.R. and Whitmore W.F., Jr., Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy, Cancer 54:744–750 (1984).
Crawford E.D., Eisenberger M.A., McLeod D., Spaulding J.T., Bensons R., Dorr F.A., Blumenstein B.A., Davis M.A. and Goodman P.J., Controlled trial of leuprolide with and without flutamide in prostatic carcinoma, New Engl. J. Med. 321:419–424 (1989).
Schally A.V., Arimura A., Baba Y., Nair R.M.G., Matsuo H., Redding T.W., Debeljuk L. and White W.F. Isolation and properties of the FSH and LH releasing hormone, Biochem. Biophys. Res. Comm. 43:393 (1971).
Schally A.V., Kastin A.J., Arimura A., et al., Basic and clinical studies with luteinizing hormone-releasing hormone (LH-RH) and its analogues, J. Reprod Fert. (Suppl.) 20:119–136 (1973).
Glode L.M. and Smith J.A., Jr., Leuprolide Study Group: Long term suppression of LH, FSH and testosterone by daily administration of leuprolide, J. Urol. 137:57–60 (1987).
Milsted R.A.V., Initiation of-LHRH monotherapy for prostate cancer, Prog, in Clin. & Biol. Res. 303:69–74 (1989).
The Leuprolide Study Group, Leuprolide versus diethylstilbestrol for metastatic prostate cancer, New Eng. J. Med. 311:1281–1286 (1984).
Peeling W.B., Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma, Suppl. to Urol. 33:5–45 (1989).
Labrie F., Dupont A., Belanger A., Lacoursiere Y., Raynaud J.P., Husson J.M., Gareau J., Fazekas A.T.A., Sandow J., Monfette G., Girard J.G., Emond J. and Houle J.G., New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens, The Prostate 4:579–594 (1983).
Lunglmayr G., On behalf of the International Prostate Cancer Study Group. “Zoladex” versus “Zoladex” plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial, Prog. in Clin.& Biol. Res. 303:145–151 (1989).
Carvalho A.P., de Moura C., Denis L., Newling D., Smith P.H., Bono A., Sylvester R., De Pauw M., Ongena P. and members of the EORTC Urological Group, Zoladex and flutamide vs. orchiectomy: A Phase III EORTC 30853 trial, Therap. Prog. in Urol. Cancers 303:129–142 (1989).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Huben, R.P. (1992). Hormone Therapy of Prostatic Bone Metastases. In: Karr, J.P., Yamanaka, H. (eds) Prostate Cancer and Bone Metastasis. Advances in Experimental Medicine and Biology, vol 324. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3398-6_33
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3398-6_33
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6501-3
Online ISBN: 978-1-4615-3398-6
eBook Packages: Springer Book Archive